NeOnc Technologies is a clinical-stage biopharmaceutical company developing novel drug treatments for intracranial malignancies, including primary brain tumors such as glioblastoma and meningioma, as well as brain metastases from other cancers. The company's lead candidates—NEO100, an intranasal perillyl alcohol delivered directly to the brain via cranial nerves to bypass the blood-brain barrier, and NEO212, a temozolomide hybrid designed to enhance brain penetration—address the critical challenge that most pharmaceutical agents cannot effectively reach the brain. NeOnc has no approved products or commercial revenue; it generates value through intellectual property licensing from USC and anticipates future revenue only upon regulatory approval and commercialization of its pipeline candidates, supported by orphan drug designations that provide extended market exclusivity.